Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › AVLN

SILVERARC CAPITAL MANAGEMENT, LLC position in AVLN

AVALYN PHARMACEUTICALS INC · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 378,352 shares of AVLN (AVALYN PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$10.8M, representing 1.37% of its reported portfolio and ranking #22 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)378.35K sh
Reported value held$10.78M
Portfolio Weight1.37%
First reportedQ2 2026
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's AVLN position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in AVLN in Q2 2026 at 330,487 shares (US$10.9M). Across 2 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 378,352 shares valued at US$10.8M — an increase of 47,865 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q2 2026 330.49K $10.88M New
Q3 2026 378.35K $10.78M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AVLN and 13F data

AVLN (AVALYN PHARMACEUTICALS INC) is a Health Care company. 113 other funds we track also report a position in AVLN — the largest reported positions include Novo Holdings A/S (US$127.8M), SR ONE CAPITAL MANAGEMENT, LP (US$108.9M), PERCEPTIVE ADVISORS LLC (US$88.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AVLN

All AVLN fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held AVLN?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in AVLN?

As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 378.35K shares of AVLN (AVALYN PHARMACEUTICALS INC), valued at $10.78M, representing 1.37% of its reported portfolio and ranking #22.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling AVLN?

In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in AVLN.

Which other funds hold AVLN?

Other major institutional holders of AVLN include Novo Holdings A/S, SR ONE CAPITAL MANAGEMENT, LP, PERCEPTIVE ADVISORS LLC, among 113 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.